Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3332532 | HIV & AIDS Review | 2009 | 4 Pages |
Abstract
Antiretroviral regimens based on human immunodeficiency virus-1 protease inhibitors are the cornerstone of combination antiretroviral therapy because of their antiviral efficacy and high genetic barrier. Protease inhibitor - containing regimens are complicated by a number of side effects, mainly diarrhea, dyslipidemia, an increased risk of myocardial infarction, diabetes and lipodystrophy. Atazanavir (ReyatazTM) is the first, originally designed as once-daily HIV-1 protease inhibitor that offers a more convenient and safer PI-containing management of HIV infection. The antiviral efficacy of atazanavir has been proven in both treatment-experienced and treatment-naive patients. In July 2008 boosted atazanavir has received registration for use in antiretroviral-naive HIV-infected population. This specific registration was based on results from 48 weeks of the Castle (BMS AI424138) study.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Ewa Siwak, Tomasz Mikula, Wojciech StaÅczak, Alicja Wiercinska-Drapalo,